Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy. (18th April 2016)

• Record Type: Journal Article
• Authors: Klein, Fritz; Neuhaus, Ruth; Eurich, Dennis; Hofmann, Jörg; Bayraktar, Sandra; Pratschke, Johann; Bahra, Marcus
• Other Names: Almasio Piero Luigi Academic Editor.
• Is Part Of: Hepatitis research and treatment. Volume 2016(2016)
• Publication Date: 2016-04-18
• Subjects: Hepatitis -- Periodicals; Hepatitis; Hepatitis; Electronic journals; Periodical; Periodicals; Fulltext; Internet Resources; Periodicals; 616.3623
• DOI: 10.1155/2016/8325467
• Languages: English
• ISSNs: 2090-1364

Abstract

Abstract : Objective. The introduction of protease inhibitors telaprevir and boceprevir in 2011 had extended the antiviral treatment options especially in genotype 1 infected hepatitis C relapsers and nonresponders to interferon/ribavirin therapy. The aim of this study was to analyze the long-term treatment efficiency of telaprevir-based triple therapy for patients with hepatitis C reinfection after orthotopic liver transplantation. Patients and Methods. We included 12 patients with histologically confirmed graft fibrosis due to hepatitis C reinfection. The treatment duration was scheduled as 12 weeks of telaprevir-based antiviral triple therapy followed by 36 weeks of dual therapy with pegylated interferon/ribavirin. The patients were followed up for two years after the end of triple therapy. Results. Of the 12 patients, 6 (50%) completed the full 48 weeks of antiviral treatment. An end of treatment response and a sustained virological response 52 weeks after the end of the antiviral treatment course were achieved in 8/12 (67%) and 7/12 (58%) patients, respectively. Conclusion. Telaprevir-based triple therapy was shown to be a long-term effective but complex treatment option for individual patients with hepatitis C graft. With the recent improvements in hepatitis C therapy options telaprevir may not be recommended as a standard therapy for this indication anymore.